AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

PCAS Capital/Financing Update 2016

Feb 15, 2016

1590_iss_2016-02-15_1f61dfa9-cd49-4f10-ac42-960a7d03cfe7.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

PCAS 8% BONDS DATED- 31/12/2016 BUY BACK

Longjumeau, 15th February 2016,

PCAS announces they have repurchased a total of 7 439 PCAS' 8% Bonds dated 31/12/2016 (FR 0010480707) out of the 33 333 bonds issued in 2007, representing approximately 22,3% of the outstanding bonds.

This operation, which will achieve savings in financial charges, fits in the PCAS' financial debt optimization strategy.

ABOUT PCAS

PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €179.1 million in 2015 and employs nearly 900 people in six countries.

For more information about PCAS: www.pcas.com

Vincent Touraille / Eric Moissenot PCAS

PCAS NewCap